Nonsteroidal anti inflammatory drug-induced hepatic disorders. Incidence and prevention

Drug Safety

Volumn 15, Issue 1, 1996, Pages 64-71

  Manoukian, Aram V ^a   Carson, Jeffrey L ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; FENOPROFEN; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; MECLOFENAMIC ACID; MEFENAMIC ACID; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PHENYLBUTAZONE; SULINDAC; TOLMETIN;

CHOLESTATIC HEPATITIS; DRUG ERUPTION; DRUG HYPERSENSITIVITY; EOSINOPHILIA; FEVER; HEPATITIS; HUMAN; INCIDENCE; JAUNDICE; LIVER DISEASE; LIVER INJURY; LIVER TOXICITY; NAUSEA; PRIORITY JOURNAL; PRURITUS; REVIEW; RISK FACTOR; VOMITING;

EID: 0029990706     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199615010-00005     Document Type: Review

References (59)

1. Bénschou C. Criteria of drug induced liver disorders: report of an international consensus meeting. J Hepatol 1990; 11: 272-6
2. Johnson JH, Jick H, Hunter JR, et al. A follow-up study of ibuprofen users. J Rheumatol 1986; 12: 549-52
3. Beard K, Belic L, Aselton P, et al. Outpatient drug-induced parenchymal liver disease requiring hospitalization. J Clin Pharmacol 1986; 26: 633-7
4. Jick H, Derby LE, Garcia Rodriguez LA, et al. Liver disease associated with diclofenac, naproxen and piroxicam. Pharmacotherapy 1992, 12: 207-12
5. Garcia Rodriguez LA, Pérez Gutthan S, Walker AM, et al. The role of non-steroidal anti-inflammatory drugs in acute liver disease. BMJ 1992; 305: 865-8
6. Pérez Gutthan S, Garcia Rodriguez LA. The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs. Epidemiology 1993; 4: 496-501
7. Carson JL, Strom BL, Duff A, et al. Safety of NSAIDs with respect to acute liver disease. Arch Intern Med 1993; 153: 1331-6
8. Garcia Rodriguez LA, Williams R, Derby LE, et al. Acute liver injury with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med 1994; 154: 311-6
9. Daniele B, Pignata S, D'Agostino L, et al. Sulindac-induced severe hepatitis. Am J Gastroenterol 1988; 83: 1429-31
10. Dhand AK, LaBrecque DR, Metzger J. Sulindac (Clinoril) hepatitis. Gastroenterology 1981; 80: 585-6
11. Whittaker SJ, Amar JN, Wanless IR, et al. Sulindac hepatotoxicity. Gut 1982; 23: 875-7
12. Lerche A, Vyberg M, Kirkegaard E. Acute cholangitis and pancreatitis associated with sulindac (Clinoril). Histopathology 1987; 11: 647-53
13. Smith FE, Lindberg PPJ. Life-threatening hypersensitivity to sulindac. JAMA 1980; 244: 269-70
14. Groux Y, Moreau M, Kuss TG. Cholestatic jaundice caused by sulindac. Can J Surg 1982; 25: 334-5
15. Kaul A, Reddy JC, Fagman E, et al. Hepatitis associated with use of sulindac in a child. J Pediatr 1981; 99: 650-1
16. Park GD, Spector R, Headstream T, et al. Serious adverse reactions associated with sulindac. Arch Intern Med 1982; 142: 1292-4
17. Wood LJ, Searle J, Mundo F, et al. Sulindac hepatotoxicity: effects of acute and chronic exposure. Aust NZJ Med 1985; 15: 397-401
18. Tarazi EM, Harter JG, Zimmerman HJ, et al. Sulindac-associated hepatic injury analysis of 91 cases reported to the Food and Drug Administration. Gastroenterology 1993; 104: 569-74
19. Breen EG, McNicholl J, Cosgrove E, et al. Fatal hepatitis associated with diclofenac. Gut 1986; 27: 1390-3
20. Schapira D, Bassan L, Nahir AM, et al. Diclofenac-associated hepatotoxicity. Postgrad Med J 1986; 62: 63-5
21. Lasgar G, Grippon P, Levy VG. Acute fatal hepatitis during treatment with diclofenac. Gastroenterol Clin Biol 1984; 8: 881-2
22. Babany G, Bernuau J, Danan G, et al. Hepatite fulminante chez une femme prenant de la glafenine et de diclofenac [letter]. Gastroenterol Clin Biol 1985; 9: 185
23. Voltaren: diclofenac sodium. The number one antiarthritic in the world. Ciba-Geigy, 1981 Aug
24. Purcell P, Henry D, Melville G. Diclofenac hepatitis. Gut 1991; 32: 1381-5
25. Helfgott SM, Sandberg-Cook J, Zakim D, et al. Diclofenac-associated hepatotoxicity. JAMA 1990; 264: 2660-2
26. Dunk AA, Walt RP, Jenkins WJ, et al. Diclofenac hepatitis. BMJ 1982; 284: 1605-6
27. Kelsey WM, Scharyj M. Fatal hepatitis probably due to indomethacin. JAMA 1967; 199: 586-7
28. Jacobs JC. Sudden death in arthritic children receiving large doses of indomethacin. JAMA 1967; 199: 932-4
29. Fenech FF, Bannister WH, Grech JL. Hepatitis with biliverdinaemia in association with indomethacin therapy. BMJ 1967; 3: 155-6
30. Cuthbert MF. Adverse reactions to nonsteroidal antirheumatic drugs. Curr Med Res Opin 1974; 2: 600-10
31. Boyer GL, Seckman CE, Welschman IR. Safety profile: fifteen years of clinical experience with ibuprofen. Am J Med 1984; 77: 25-34
32. Freeland GR, Northington RS, Hedrich DA, et al. Hepatic safety of two analgesics used over the counter: ibuprofen and aspirin. Clin Pharmacol Ther 1988; 43: 473-9
33. Lewis JH. Hepatic toxicity of nonsteroidal anti-inflammatory drugs. Clin Pharm 1984; 3: 128-38
34. Stempel DA, Miller JJ. Lymphopenia and hepatic toxicity with ibuprofen. J Pediatr 1977; 90: 657-8
35. Zimmerman HJ, Maddrey WC. Toxic and drug induced hepatitis. In: Schiff L, Schiff ER, editors. Diseases of the liver, 7th ed. Philadelphia: JB Lippencott, 1993: 707-83
36. Stricker BHC, Spoelstra P. Drug-induced liver injury. Amsterdam: Elsevier, 1985: 45-76
37. Bravo JF, Jacobson MP, Mertens BF. Fatty liver and pleural effusion with ibuprofen therapy. Ann Intern Med 1977; 87: 200-1
38. Lee CY, Finkler A. Acute intoxication due to ibuprofen overdose. Arch Pathol Lab Med 1986; 110; 747-9
39. Cuthbert MF. Adverse reactions to nonsteroidal antirheumatic drugs. Curr Med Res Opin 1974; 2: 600-10
40. Barron KS, Person DA, Brewer EJ. The toxicity of nonsteroidal anti-inflammatory drugs in juvenile rheumatoid arthritis. J Rheumatol 1982; 9: 149-55
41. Stricker BHC, Spoelstra P. Drug-induced liver injury. Amsterdam: Elsevier, 1985: 45-76
42. Bass BH. Jaundice associated with naproxen [letter]. Lancet 1974; 1: 998
43. Victorino RMM, Silvera JCB, Baptista A, et al. Jaundice associated with naproxen. Postgrad Med J 1980; 56: 368-70
44. Law IP, Knight H. Jaundice associated with naproxen [letler]. N Engl J Med 1976; 295: 1201
45. Lagarriga J. Naproxen e icteria [letter]. Rev Scand Milit 1975; 29: 250
46. Cuthbert MF. Adverse reactions to nonsteroidal antirheumatic drugs. Curr Med Res Opin 1974; 2: 600-10
47. Zimmerman HJ. Update of hepatotoxicity due to classes of drugs in common use: nonsteroidal drugs, anti-inflammatory drugs, antibiotics, antihypertensives and cardiac and psychotropic drugs. Semin Liver Dis 1990; 10: 322-38
48. Zimmerman HJ. Hepatic effects of oxaprozin. Semin Arthritis Rheum 1986; 15 (3) Suppl. 2: 35-9
49. Lewis JH. Hepatic toxicity of nonsteroidal anti-inflammatory drugs. Clin Pharm 1984; 3: 128-38
50. Benjamin SB, Ishak KG, Zimmerman HJ, et al. Phenylbutazone liver injury: a clinical-pathologic survey of 23 cases and review of the literature. Hepatology 1981; 1: 255-63
51. Brogden RN, Heel RC, Speight TM, et al. Tolmetin: a review of its pharmacological properties and therapeutic efficacy in rheumatic diseases. Drugs 1978; 15: 429-50
52. Craig GL, Buchanan WW. Antirheumatic drugs: clinical pharmacology and therapeutic use. Drugs 1980; 20: 453-84
53. Hartman H. Prolonged cholestatic jaundice and leukopenia associated with piroxicam. Gastroenterology 1984; 22: 343-5
54. Lee SM, O'Brien CJ, Williams R, et al. Subacute hepatic necrosis induced by piroxicam. BMJ 1986; 293: 540-1
55. Bismuth H, Samuel D, Gugenheim J, et al. Emergency liver transplantation for fulminant hepatitis. Ann Intern Med 1987; 107: 337-41
56. Planas R, Leon RD, Quer JC, et al. Fatal submassive necrosis of the liver associated with piroxicam. Am J Gastroenterol 1990; 85: 468-70
57. Caballeria E, Masso RM, Arago JV, et al. Piroxicam hepatotoxicity. Am J Gastroenterol 1990; 85: 898-9
58. Hepps KS, Maliha GM, Estrada R, et al. Severe cholestatic jaundice associated with piroxicam. Gastroenlerology 1991; 101: 1737-40
59. Lewis JH. Hepatic toxicity of nonsteroidal anti-inflammatory drugs. Clin Pharm 1984; 3: 128-38